NT5E Recombinant Monoclonal Antibody

說明書

中文名稱：

NT5E重組抗體
貨號：

CSB-RA723415MA1HU
規格：

￥1320
圖片：
Overlay Peak curve showing PC3 cells surface stained with CSB-RA723415MA1HU (red line) at 1:100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-human IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was mouse IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSB-RA723415MA1HU NT5E重組單克隆抗體是針對CD73抗原研發的高特異性檢測工具。該抗體靶向的NT5E（CD73）是一種膜結合外核苷酸酶，通過催化AMP水解生成腺苷，在調節腫瘤微環境免疫抑制及細胞信號傳導中發揮關鍵作用。經嚴格驗證，本產品在ELISA、免疫組化（IHC）和流式細胞術（FC）等多種平臺均表現優異，能特異性識別天然構象的CD73蛋白。在IHC應用中可清晰顯示組織樣本中靶蛋白的定位分布，流式檢測則能精準分析細胞表面CD73的表達水平。其重組單克隆特性確保了批次間高度一致性，為腫瘤微環境研究、免疫檢查點調控機制探索及癌癥生物學相關實驗提供可靠工具。推薦使用稀釋度為IHC 1:50-1:200，FC 1:50-1:200，適用于福爾馬林固定石蠟包埋組織切片或懸浮細胞樣本，助力科研人員深入探究CD73在免疫代謝及腫瘤免疫逃逸中的功能機制。
Uniprot No.：

P21589
基因名：

NT5E
別名：

NT5E Recombinant Monoclonal Antibody
反應種屬：

Human
免疫原：

Recombinant Human NT5E protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

hIgG1
純化方式：

Affinity-chromatography
克隆號：

8G5
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC, FC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200
FC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Flow cytometry (FC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
基因功能參考文獻：
1. Changes in the local expression and activity of CD39 and CD73 in calcified valves suggest their potential role in calcific aortic valve disease. PMID: 30056298
2. High expression of NT5E is associated with Prostate Cancer. PMID: 29916747
3. Case Report: identify novel mutations in the NT5E gene in patient with calcification of joints and arteries. PMID: 28825389
4. High CD73 expression is associated with breast cancer. PMID: 29047106
5. High CD73 expression is associated with neoplasms. PMID: 29514610
6. NT5E-targeting miRNAs (miR-30b and miR-340) function as tumor suppressors PMID: 29155108
7. soluble CD73 might be used as serologic prognostic biomarker in patients with metastatic melanoma patients. PMID: 29202855
8. High CD73 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity. PMID: 29367423
9. analysis of how inhibitors block human CD73 and block efficiently its enzymatic function in the low micromolar range through a non-competitive inhibition mechanism PMID: 29377887
10. The Ecto-5'nucleotidase, together with alkaline phosphatase, also expressed apically in oviductal epithelium, complete the hydrolysis sequence by dephosphorylating AMP to adenosine. PMID: 29273916
11. this paper shows that simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro PMID: 28389406
12. high levels of CD73 are significantly associated with reduced overall survival in patients with head and neck squamous cell carcinoma PMID: 27557512
13. Studied role of miR-30a in colorectal cancer(CRC). Found miR-30a is downregulated in CRC, and it inhibits cell proliferation in CRC by reducing expression of CD73. PMID: 28464916
14. we demonstrated the existence of CSCs in both cultured ccRCC cell line and tissues, and CD73 as a cell-surface biomarker for ccRCC CSC-like cells. PMID: 28404888
15. Induction of ecto-5'-nucleotidase/CD73 by radiation contributes to the radiosensitivity of T24 urinary bladder cancer cell line. PMID: 29305710
16. Report prognostic impact of CD73 expression in non-small lung cancers. PMID: 28060732
17. Data show that MiR-422a and its target CD73 are involved in early loco(regional) recurrence of head and neck squamous cell carcinoma (HNSCC) tumors and are targets for personalized medicine. PMID: 27281619
18. HPV+ cervical cancer cells express higher levels of CD73 than HPV- cells, and this expression is associated with the production of larger amounts of adenosine, as well as a stronger inhibition of proliferation, activation, and cytotoxic activity of CD8+ T cells via interaction with A2A adenosine receptor PMID: 28950987
19. High CD73 expression is associated with Melanoma Metastasis. PMID: 28652244
20. Hippocampal astrogliosis observed in medial temporal lobe epilepsy patients was accompanied by a proportionate increase in A2A receptor and ecto-5'-nucleotidase/CD73 immunoreactivities. PMID: 27650530
21. High CD73 expression is associated with cervical cancer. PMID: 28202050
22. Endogenous Plastic Somatic (ePS) cells in a latent state, i.e. lacking SOX2, OCT3/4 and NANOG (SON) expression, in non-diseased breast specimens through immunohistochemical analysis of previously identified ePS-specific biomarkers (CD73(+), EpCAM(+) and CD90(-)). PMID: 27705752
23. Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. PMID: 28193736
24. CD73 polymorphisms play a role in calciphylaxis development in dialysis patients. PMID: 28212442
25. CD73 expression is upregulated in NSCLC and is correlated with a decrease in miR-30a-5p expression. PMID: 28158983
26. This study found that in septic critically ill patients the soluble CD73 levels were generally low and showed a further decrease from 0h to 24h. Moreover, the sCD73 levels were higher in acute kidney injury (AKI) versus non-AKI patients and in non-survivors with severe sepsis than in survivors, but were not independently associated either with the development of AKI or 90-day mortal PMID: 27732656
27. concluded that CD39 and CD73 are molecular targets for the development of drugs for ALF patients care PMID: 27899277
28. Genetic polymorphism of NT5E may contribute to the pathogenesis of calcific aortic valve disease. PMID: 27906615
29. Oxidized low density lipoproteins modulate CD39 and CD73 activity in the endothelium. PMID: 27906627
30. CD73 may play an important role in breast cancer stem cells. PMID: 27670764
31. This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface as well as CD39 and CD73 expressions on platelets of sickle cell anemia treated patients. PMID: 27044834
32. Aim of the present study was to investigate the role of CD73 in glioma blood vessels; results found that the expression of CD73 in glioma vascular cells is significantly decreased, and this reduction may down-regulate the expression of brain microvascular endothelial tight junction-related proteins PMID: 26884147
33. These results provide a finely mapped epitope that can be targeted for selective, potent, and non-competitive inhibition of CD73, as well as establish a strategy for inhibiting enzymes that function in both membrane-bound and soluble states. PMID: 26854859
34. CD73 promotes the growth of human colorectal cancer cells through EGFR and the b-catenin/cyclin D1 signaling pathway. CD73 may be used as a valuable biomarker of colorectal cancer. PMID: 26708311
35. Our study revealed that CD73 is an independent prognostic factor in prostate cancer. PMID: 26253870
36. The NT5E gene is involved in both intrinsic and acquired resistance to platinum-based drugs in ovarian cancer. [meta-analysis] PMID: 26629888
37. CD73 expression was significantly correlated with the invasion into adjacent organs. PMID: 26691441
38. report on a Chinese family with CALJA and novel compound heterozygous mutations (c.1360G>A (p.Gly454Arg) and c.1387C>T (p.Arg463X)) in NT5E PMID: 26178434
39. findings reveal that CD73-generated adenosine promotes epithelial integrity and suggest why loss of CD73 in endometrial cancer allows for tumor progression PMID: 26642367
40. CD73 activity from any host cell type is not required for the monocyte/macrophage polarization in the peritoneum towards a pro- or an anti-inflammatory phenotype in vivo PMID: 26258883
41. these data suggest a possible role for CD73 and A2A in inflammation observed in patients with T2D and obesity mediated via apoptosis. PMID: 25770019
42. This study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in high-grade serous ovarian cancers. PMID: 26363007
43. role of CD73 and CD39 ectonucleotidases in T cell differentiation PMID: 26226423
44. Expression of NPP1 and 5'-nucleotidase by valve interstitial cells promotes the mineralization of the aortic valve through A2aR and a cAMP/PKA/CREB pathway. PMID: 25644539
45. Although upregulated CD73 expression in tumor cells correlates with a poor prognosis in patients with rectal adenocarcinoma, the combination of CD73 expression in malignant epithelial cells and tumor stroma may have a better prognostic value PMID: 25677906
46. rs9444348 heterozygosity is associated with increased risk of post-traumatic epilepsy development after brain injury. PMID: 26040919
47. Species-specific CD73 regulation, with potential significance to cancer, fibrosis, and other diseases characterized by changes in CD73 expression and function. PMID: 25298403
48. The Nt5e(-/-) targeted mutant mice recapitulate some, but not all, features of ACDC and serve as a model system to study pharmacologic interventions for ectopic mineralization. PMID: 25486201
49. CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. PMID: 25402681
50. It decompose ATP and produce adenosine, which regulates immunity via adenosine receptor. PMID: 25675814
顯示更多

收起更多
相關疾?。?/div>
Calcification of joints and arteries (CALJA)
亞細胞定位：

Cell membrane; Lipid-anchor, GPI-anchor.
蛋白家族：

5'-nucleotidase family
數據庫鏈接：

HGNC: 8021

OMIM: 129190

KEGG: hsa:4907

STRING: 9606.ENSP00000257770

UniGene: Hs.153952

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human